PMA Slowdown To Persist In ’04, McClellan Says; User Fee Hikes To Follow?
This article was originally published in The Gray Sheet
Executive Summary
FDA expects the rate of new product applications to continue declining for the foreseeable future, despite a series of review cycle improvement initiatives begun in January